Intellia Therapeutics Receives Orphan Drug Designation for NTLA-2002 in the EU
1 Mins read
Intellia Therapeutics, a leading biotechnology company, has recently been granted orphan drug designation by the European Commission for their investigational therapy, NTLA-2002….